On September 2, 2022 LamKap Bio beta reported to present data on NILK-2401 ± NILK-2301 programs SITC (Free SITC Whitepaper) 37th Annual Meeting 2022 (Press release, LamKap Bio Group, SEP 2, 2022, View Source [SID1234618948])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) (Free SITC Whitepaper) will host the 37th Annual Meeting & Pre-Conference Programs November 8-12, 2022. LamKap Bio beta is very pleased to present for the first time preclinical data on the development of NILK-2401 (CEAxCD47) ± NILK-2301 (CEAxCD28) bispecific antibodies for immunotherapy of patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) expressing solid tumors.

"Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer" will be presented on site in the Poster Hall on November 10 (abstract no. 853).

A pdf file will be made available for download after presentation at the meeting.